The size of the Europe Electroceuticals Market was worth USD 30.77 billion in 2024 and is estimated to be growing at a CAGR of 7.4%, to reach USD 43.97 billion by 2029.
The population crossing age above 60 is significantly growing in the European countries and the probability of diagnosing with various diseases such as Parkinson’s, Alzheimer’s, epilepsy and others for the aged population is very high and demands more electroceutical devices for the treatment purposes. Hence, the rising aging population in the European continent is expected to boost the market growth.
The R&D investments for the new and innovative therapies have a received a spike in Europe, which is estimated to favour the market during the forecast period. Increasing number of approvals for the new and advanced electroceutical products and growing number of strategies adopted by the market participants are expected to take the market to the next level in the near future. The number of hospitals in the European region is growing year-by-year and is a positive sign to the market growth.
High costs associated with these products is a key factor expected to restrict the market growth to a small extent. Strict regulations to be followed during the approval of new products and therapies and unfavourable reimbursement policies are the factors that obstruct the market growth of the Europe region.
Key players operating in the Europe Electroceuticals Market profiled in this report are Medtronic plc, St. Jude Medical, Inc., Boston Scientific Corporation, Cochlear Limited, Sonova Holding AG, LivaNova PLC, Biotronik, Nevro Corporation, Second Sight Medical Products, Inc., and ElectroCore LLC.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region